Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | TTR | P02766 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | PGR | P06401 | 3/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | ESR1 | P03372 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA5A | P35218 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.36 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2999085 | 0.90 | PGR (0.47) | MAPTLMNAMEN1KMT2ACYP3A4 | |
| SCHEMBL13864993 | 0.74 | BACE1 (0.50) | MAPTLMNAMEN1KMT2ACYP3A4 | |
| SCHEMBL7114628 | 0.74 | CYP3A4 (0.47) | MAPTLMNAMEN1KMT2ACYP3A4 | |
| SCHEMBL21584054 | 0.73 | NPC1 (0.40) | MAPTLMNATTRSMN1; SMN2CA5A | |
| SCHEMBL7225909 | 0.72 | MAPT (0.47) | MAPTLMNAMEN1KMT2ACYP3A4 | |
| SCHEMBL2010436 | 0.70 | LMNA (0.59) | MAPTLMNAMEN1KMT2ACYP3A4 | |
| SCHEMBL28118605 | 0.69 | CYP3A4 (0.47) | MAPTLMNAMEN1KMT2ACYP3A4 | |
| SCHEMBL3453107 | 0.69 | LMNA (0.50) | MAPTLMNAMEN1KMT2ACYP3A4 | |
| SCHEMBL14710190 | 0.69 | LMNA (0.46) | MAPTLMNAMEN1KMT2ACYP3A4 | |
| SCHEMBL34461299 | 0.68 | PGR (0.43) | MAPTLMNAMEN1KMT2ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630561-B2 | Tricyclic derivatives inhibitor, preparation method, and applications thereof | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2026-05-19 | — | — | US | disclosed |
| EP-3805231-B1 | INHIBITOR CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | JIANGSU HANSOH PHARMACEUTICAL GROUP CO LTD (CN) | 2024-10-16 | — | — | EP | disclosed |
| CN-113227101-B | Salt or crystal form containing tricyclic derivative and pharmaceutical composition thereof | 上海翰森生物医药科技有限公司 | 2024-10-11 | — | — | CN | disclosed |
| CN-114835729-B | Inhibitor containing tricyclic derivatives, preparation method and application thereof | 江苏豪森药业集团有限公司 | 2024-05-31 | — | — | CN | disclosed |
| CN-112830935-B | Crystal form containing tricyclic derivative free alkali and pharmaceutical composition thereof | 上海翰森生物医药科技有限公司 | 2023-12-22 | — | — | CN | disclosed |
| US-20230014383-A1 | THREE FUSED RING DERIVATIVE-CONTAINING SALT OR CRYSTAL FORM AND PHARMACEUTICAL COMPOSITION THEREOF | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-01-19 | — | — | US | disclosed |
| CN-114835729-A | Tricyclic derivative inhibitor, preparation method and application thereof | 江苏豪森药业集团有限公司 | 2022-08-02 | — | — | CN | disclosed |
| CN-110785423-B | Tricyclic derivative inhibitor, preparation method and application thereof | 江苏豪森药业集团有限公司 | 2022-07-26 | — | — | CN | disclosed |
| US-20210221822-A1 | TRICYCLIC DERIVATIVES INHIBITOR, PREPARATION METHOD, AND APPLICATIONS THEREOF | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2021-07-22 | — | — | US | disclosed |
| US-20210221822-A1 | TRICYCLIC DERIVATIVES INHIBITOR, PREPARATION METHOD, AND APPLICATIONS THEREOF | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2021-07-22 | — | — | US | disclosed |
| WO-2021104146-A1 | THREE FUSED RING DERIVATIVE-CONTAINING SALT OR CRYSTAL FORM AND PHARMACEUTICAL COMPOSITION THEREOF | 上海翰森生物医药科技有限公司 | 2021-06-03 | — | — | WO | disclosed |
| EP-3805231-A1 | INHIBITOR CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (CN) | 2021-04-14 | — | — | EP | disclosed |
| EP-3805231-A1 | INHIBITOR CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (CN) | 2021-04-14 | — | — | EP | disclosed |
| WO-2019228341-A1 | INHIBITOR CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 江苏豪森药业集团有限公司 (CN) | 2019-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210221822-A1 | TRICYCLIC DERIVATIVES INHIBITOR, PREPARATION METHOD, AND APPLICATIONS THEREOF | PIK3CA, PIK3CD, PIK3CB | MAPT 2360/4885LMNA 1526/4885MEN1 2569/4885 |
| US-20230014383-A1 | THREE FUSED RING DERIVATIVE-CONTAINING SALT OR CRYSTAL FORM AND PHARMACEUTICAL COMPOSITION THEREOF | AKT2, AKT3, PIK3R5 | MAPT 944/4885LMNA 4011/4885MEN1 1659/4885 |
| US-12630561-B2 | Tricyclic derivatives inhibitor, preparation method, and applications thereof | PIK3CA, PIK3R1, PIK3CD | MAPT 4878/4885LMNA 2893/4885MEN1 3825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.